IONA Nx NIPT Workflow logo

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

TGA approves IONA® Nx for sale in Australia

Manchester, UK – 13 August 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its IONA® Nx NIPT workflow (‘IONA® Nx’), a non-invasive prenatal test (‘NIPT’), has been approved by Australia’s Therapeutics Goods Association (‘TGA’) as a medical device Class 3, allowing Southern Cross Diagnostics, Yourgene’s Australian distributor, to commence sales.

The TGA is the regulatory body for therapeutic goods in Australia. It is a Division of the Australian Department of Health established under the Therapeutic Goods Act 1989.

Australia is the first major market outside of the UK / EU to have granted approval to IONA® Nx, following on from the CE-IVD approval it received on the 15 June, stating that the IONA® Nx was being readied for commercial launch in other geographies. The IONA® Nx is an in vitro nucleic acid screening test that measures the likelihood that a pregnant woman is carrying a fetus with Trisomy 13, 18 or 21. It is a laboratory based test that has been developed to run on the Illumina’s NextSeq 550Dx instrument, a next generation sequencing (“NGS”) platform.

It is estimated that the birth rate in Australia is 300,000 per annum1 and the increase of women having their first child over the age of 30 (risen from 23% in 1991 to 48% in 2016)1 is expected to result in increased demand for NIPT, demonstrating the importance of this target market for the Group.

Lyn Rees, CEO of Yourgene Health plc, stated: “This is a key milestone for the Company, which opens up one of the major healthcare markets in the world to our leading product and complements our existing product sales in that country. Southern Cross is already carrying out a superb job operating as our sole distributor for our reproductive health portfolio of PCR tests, in addition to our DPYD oncology product, which received TGA approval back in February this year. We look forward to mirroring that success with our NIPT product.”

1 – https://aifs.gov.au/facts-and-figures/births-in-australia

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Yourgene Health plc

Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 669 8122

investors@yourgene-health.com

Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / James Caithie / Ludovico Lazzaretti
 Tel: +44 (0)20 7213 0880
N+1 Singer (Joint Corporate Broker)
Aubrey Powell / Tom Salvesen / George Tzimas
Tel: +44 (0)20 7496 3000

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Walbrook PR Ltd (Media and Investor Relations)

Paul McManus / Lianne Cawthorne

Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com

Mob: 07980 541 893 Mob: 07584 391 303

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group’s products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene’s commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

About Coastal Genomics

The “Why” behind Coastal Genomics is that good science should not hinge on the fickle nature of manual bench science. This is a shared perspective as evidenced by the continued move to automate life science protocols. Techniques that compromise on result quality in exchange for automatability can be a viable option for some workflows. Inevitably though, the demands of new applications that are high value and high throughput in nature come to require high quality input that can only be delivered by golden standard bench techniques. Please visit our website at www.coastalgenomics.com to learn more about how we help secure quality sample preparation.